Literature DB >> 11029331

An investigation into causative factors in patients with bronchiectasis.

M C Pasteur1, S M Helliwell, S J Houghton, S C Webb, J E Foweraker, R A Coulden, C D Flower, D Bilton, M T Keogan.   

Abstract

Bronchiectasis is a pathologic description of lung damage characterized by inflamed and dilated thick-walled bronchi. These findings may result from a number of possible causes and these may influence treatment and prognosis. The aim of this study was to determine causative factors in 150 adults with bronchiectasis (56 male, 94 female) identified using high-resolution computerized tomography. Relevant factors were identified in the clinical history; cystic fibrosis gene mutation analysis was performed; humoral immune defects were determined by measuring immunoglobulins, IgG subclasses and functional response to Pneumovax II vaccine; assessment was made of neutrophil function (respiratory burst, adhesion molecule expression, and chemotaxis); ciliary function was observed and those likely to have allergic bronchopulmonary aspergillosis (ABPA) were identified. Causes identified were: immune defects (12 cases), cystic fibrosis (4), Young's syndrome (5), ciliary dysfunction (3), aspiration (6), panbronchiolitis (1), congenital defect (1), ABPA (11), rheumatoid arthritis (4), and early childhood pneumonia, pertussis, or measles (44). Intensive investigation of this population of patients with bronchiectasis led to identification of one or more causative factor in 47% of cases. In 22 patients (15%), the cause identified had implications for prognosis and treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11029331     DOI: 10.1164/ajrccm.162.4.9906120

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  131 in total

1.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

Authors:  J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Authors:  Amy E Seitz; Kenneth N Olivier; Jennifer Adjemian; Steven M Holland; D Rebecca Prevots
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

3.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

4.  New Zealand national incidence of bronchiectasis "too high" for a developed country.

Authors:  J Twiss; R Metcalfe; E Edwards; C Byrnes
Journal:  Arch Dis Child       Date:  2005-05-04       Impact factor: 3.791

5.  Assessing immune function in adult bronchiectasis.

Authors:  P T King; P Hutchinson; P W Holmes; N J Freezer; V Bennett-Wood; R Robins-Browne; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

6.  Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 7.  Treatment of bronchiectasis in adults.

Authors:  Nick H T ten Hacken; Peter J Wijkstra; Huib A M Kerstjens
Journal:  BMJ       Date:  2007-11-24

Review 8.  A review of non-cystic fibrosis pediatric bronchiectasis.

Authors:  Eric J Boren; Suzanne S Teuber; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

9.  Surgical treatment of bronchiectasis: a retrospective observational study of 138 patients.

Authors:  Reda E Al-Refaie; Sameh Amer; Mohamed El-Shabrawy
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

10.  Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Hui-Min Li; Jing-Jing Yuan; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.